Clene reports Q3 net loss of $8.0M; cash $14.6M; awaits FDA meeting on accelerated ALS approval

Clene Inc.

Met with FDA on Nov 1 to discuss accelerated approval pathway for CNM-Au8 in ALS; awaiting meeting minutes.
Cash, cash equivalents and marketable securities of $14.6M as of Sep 30, 2024, down from $35.0M at Dec 31, 2023.
Raised $7.3M in October registered direct offering and private placements; runway extended into Q1 2025.
Amended Avenue debt facility to defer principal payments and extend maturity to Q2 2025.
Q3 2024 net loss $8.0M ($1.22 per share) vs net loss $2.4M ($0.38 per share) in Q3 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.